Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Dyne Therapeutics, Inc. (DYN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $17.58 per share as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-07-29
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $17.58.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $17.48.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $17.92.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $17.86.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $17.58 10-Q · filed 2026-07-29 |
| 2026-03-31 | $17.48 10-Q · filed 2026-05-11 |
| 2025-12-31 | $17.92 10-K · filed 2026-03-02 |
| 2025-09-30 | $17.86 10-Q · filed 2025-11-05 |
| 2025-06-30 | $19.12 10-Q · filed 2025-07-28 |
| 2025-03-31 | $19.33 10-Q · filed 2025-05-08 |
| 2024-12-31 | $19.47 10-K · filed 2025-02-27 |
| 2024-09-30 | $16.95 10-Q · filed 2024-11-12 |
| 2024-06-30 | $14.00 10-Q · filed 2024-08-12 |
| 2024-03-31 | $12.92 10-Q · filed 2024-05-02 |
| 2023-12-31 | $10.48 10-K · filed 2024-03-05 |
| 2023-09-30 | $10.43 10-Q · filed 2023-10-30 |
| 2023-06-30 | $10.33 10-Q · filed 2023-08-03 |
| 2023-03-31 | $9.83 10-Q · filed 2023-05-11 |
| 2022-12-31 | $9.59 10-K · filed 2023-03-02 |
| 2022-09-30 | $9.15 10-Q · filed 2022-11-03 |
| 2022-06-30 | $9.15 10-Q · filed 2022-08-04 |
| 2022-03-31 | $9.30 10-Q · filed 2022-05-02 |
| 2021-12-31 | $9.35 10-K · filed 2022-03-10 |
| 2021-09-30 | $8.73 10-Q · filed 2021-11-04 |
| 2021-06-30 | $8.17 10-Q · filed 2021-08-05 |
| 2021-03-31 | $7.55 10-Q · filed 2021-05-06 |
| 2020-12-31 | $6.97 10-K · filed 2021-03-04 |
| 2020-09-30 | $6.78 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |